Drug repositioning greatly reduces drug development costs and time by discovering new indications for existing drugs. With the development of technology and large-scale biological databases, computational drug repositioning has increasingly attracted remarkable attention, which can narrow down repositioning candidates. Recently, graph neural networks (GNNs) have been widely used and achieved promising results in drug repositioning. However, the existing GNNs based methods usually focus on modeling the complex drug-disease association graph, but ignore the semantic information on the graph, which may lead to a lack of consistency of global topology information and local semantic information for the learned features. To alleviate the above challenge, we propose a novel drug repositioning model based on graph contrastive learning, termed DRGCL. First, we treat the known drug-disease associations as the topology graph. Second, we select the top- $K$ similar neighbor from drug/disease similarity information to construct the semantic graph rather than use the traditional data augmentation strategy, thereby maximally retaining rich semantic information. Finally, we pull closer to embedding consistency of the different embedding spaces by graph contrastive learning to enhance the topology and semantic feature on the graph. We have evaluated DRGCL on four benchmark datasets and the experiment results show that the proposed DRGCL is superior to the state-of-the-art methods. Especially, the average result of DRGCL is 11.92% higher than that of the second-best method in terms of AUPRC. The case studies further demonstrate the reliability of DRGCL. Experimental datasets and experimental codes can be found in https://github.com/Jiaxiao123/DRGCL .
13 September 2023 in IEEE Journal of Biomedical and Health Informatics
Accurately predicting drug-target binding affinity plays a vital role in accelerating drug discovery. Many computational approaches have been proposed due to costly and time-consuming of wet laboratory experiments. In the input representation, most methods only focus on the target sequence properties or target structure properties while ignore the overall contribution. Therefore, we develop a novel fusion protocol based on multiscale convolutional neural networks and graph neural networks, named CGraphDTA, to predict drug-target binding affinity using target sequence and structure. Unlike existing methods, CGraphDTA is the first model constructed with target sequence and structure as input. Concretely, the multiscale convolutional neural networks are utilized to extract target and drug presentation from sequence, graph neuralnetworksareemployedtoextractgraphpresentation from target and drug molecular structure. We compare CGraphDTA with the state-of-the-art methods, the results show that our model outperforms the current methods on the test sets. Furthermore, we conduct ablation studies, biological interpretation examination and drug selectivity evaluation, all results suggest that CGraphDTA is a useful tool to predict drug-target binding affinity and accelerate drug discovery. The resource codes are available at https://github.com/CSUBioGroup/CGraphDTA .
Previous studies reported that DNA damage repair (DDR) genes may play an important role in HIV-1 infection. The MRE11 gene, a member of the MRN complex, plays an essential part in the homologous recombination pathway, which is one of the classical DDR pathways. Previous reports have demonstrated that MRE11 has an effect on HIV-1 replication. However, the role of SNPs in the MRE11 gene and their impact on HIV-1 infection and AIDS progression remain unknown. In this study, 434 MSM HIV-1-infected patients in northern China and 431 age-matched healthy controls were enrolled. Five SNPs (rs2155209, rs10831234, rs13447720, rs601341 and rs11020803) at the MRE11 gene were genotyped. Another series of cases (409 MSM HIV-1-infected patients) and controls (403 age-matched healthy males) were recruited as the validation set. In our study, rs10831234 showed differences in allele frequencies between cases and controls (P = 0.005). Additionally, there was an association between rs10831234 and HIV-1 infection susceptibility in dominant and additive models (P = 0.005 and P = 0.006, respectively). All significant associations were replicated in the validation set, and the associations were still significant after Bonferroni correction for multiple testing when the two data sets were combined. Furthermore, in haplotype association analyses between the case and control groups, the frequencies of the haplotypes Crs11020803Crs10831234 and Trs11020803Trs10831234 showed significant differences (P = 0.0181 and P = 0.0068, respectively). We demonstrated that the MRE11 rs10831234-T allele may confer increased risk of HIV-1 infection.
Accurate prediction of drug–target binding affinity is essential for drug discovery. However, existing methods face limitations in capturing local and global molecular features and in effectively integrating protein and ligand representations for interaction modeling. Here, we present HierL2GDTA, a sequence-based hierarchical framework for predicting binding affinity. Pretrained protein and molecular representations are processed by multi-scale convolutions to extract local features, followed by a bidirectional gated recurrent unit and dilated convolutions to capture broader protein and ligand context, respectively. A modified Transformer encoder integrates global protein context and ligand features through sequential cross-attention to model intramolecular and intermolecular dependencies. HierL2GDTA outperformed the evaluated baseline methods on both BindingDB and Davis. Further evaluations demonstrated the effectiveness of the model components and favorable predictive performance across selected kinase families. Attention visualization highlighted molecular substructures associated with protein binding, while retrospective screening ranked known inhibitors of disease-associated targets among the leading candidates. These results indicate that HierL2GDTA is an effective deep learning method for binding affinity prediction, with potential application for target-based drug screening.